Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...
Yahoo Finance23d
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...
Reuters24d
Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion
The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors. The therapy is a ...
Ibj.com24d
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors. The therapy is designed to target ...
Wall Street Journal23d
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal
The drugmaker said Monday it is acquiring Scorpion and its STX-478 program, with shareholders of the private company set to receive up to $2.5 billion in an upfront payment and subsequent payments ...
The Business Journals24d
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Scorpion Therapeutics Inc. is selling STX-478, its lead drug for breast cancer and other advanced solid tumors that is currently in a Phase 1/2 clinical trial. Lilly (NYSE: LLY) will pay Scorpion ...
Business Insider23d
Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily ...